Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09PCL
|
|||
| Drug Name |
JNJ-64565111
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66] | Phase 2 | [1] | |
| Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 1 | [2] | ||
| Company |
Janssen Research & Development Raritan, NJ
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glucagon (GCG) | Target Info | Agonist | [2] |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Thermogenesis | ||||
| Insulin secretion | ||||
| Glucagon signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03486392) A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.